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Received January 28, 2014; accepted May 9, 2014AbstractBackground: Omeprazole (OMP), a proton pump inhibitor, is a highly effective drug for the management of acid-related disorders. Infections
resulting from cytotoxin antigen A (CagA) positive Helicobacter pylori strains have been associated with higher grades of gastric mucosal
inflammation. Nuclear factor (NF)-kB activation has been reported to participate in H. pylori-induced gastritis in humans. The complex
interaction of OMP on the H. pylori and NF-kB related molecular mechanisms within the gastric mucosa remains unclear. In the present study,
we investigated OMP, specifically its effects on NF-kB activation, and COX-2, IL-6, and IL-8 production in gastric cells (Kato-III cells) treated
with CagA positive (CagAþ) and negative (CagAe) H. pylori strains.
Methods: Kato-III cells were stimulated with H. pylori water extracts (HPE) containing ATCC 43504 (CagAþ) and ATCC 51932 (CagAe)
strains. NF-kB activation, inhibitory IkB expression and phosphorylation, and cyclooxygenase (COX)-2, interleukin (IL)-6, and IL-8 expression
were assessed in the absence and presence of OMP.
Results: Both CagAþ and CagAe HPE induced NF-kB activation, whereas OMP suppressed NF-kB activation in the CagAe strain. HPE
demonstrated a similar effect on IkB protein expression in the absence and presence of OMP. OMP alone decreased IkB phosphorylation without
promoting NF-kB and IkB expression. Additionally, both CagAþ and CagAe HPE induced COX-2 expression, but no significant effect on IL-6
and IL-8. However, OMP downregulated the transcription of COX-2, IL-6, and IL-8 in CagAe HPE treated cells.
Conclusion: Using the Kato-III cells model, H. pylori induces NF-kB activation in a CagA-independent manner. Both CagAþ HPE and CagAe
HPE induced COX-2 gene expression, but not for IL-6 and IL-8 expression. However, OMP suppressed NF-kB activation via a downregulation
of IkB phosphorylation in CagAe HPE treated condition. OMP also suppressed CagAe H. pylori induced-transcription of proinflammatory
COX-2, IL-6, and IL-8. OMP may provide different effects on CagAþ and CagAe H. pylori infection conditions.
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Helicobacter pylori colonize the stomach, where it can
induce peptic ulcers, mucosa-associated lymphoid tissue lym-
phoma, and gastric adenocarcinoma.1,2 In human and animal
studies, H. pylori has been shown to induce inflammation-
associated gene expression, including the activation of nuclearociation. All rights reserved.
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and cyclooxygenase-2 (COX-2) expression.6
NF-kB is a ubiquitous transcription factor that plays a major
regulatory role in inflammation. In resting cells, NF-kB is
retained within the cytoplasm and bound to a family of inhibi-
tory IkB proteins. A variety of stimuli rapidly induce the
translocation of NF-kB into the nucleus via the phosphorylation
of IkB.7 AH. pylori infection can induce the phosphorylation of
IkB, which contributes to the activation of NF-kB.8 Pathogenic
strains of H. pylori carry a type IV secretion system (T4SS)
responsible for the injection of the oncoprotein cytotoxin anti-
gen A (CagA) into host cells.9 However,H. pylori has also been
demonstrated to induceNF-kB expression in a type IV secretion
system-dependent, but CagA -independent manner.10 IL-6, IL-
8, and COX-2, as well as their transcriptional regulation, are, in
part, under the control of NF-kB.11e13
Proton pump (Hþ/Kþ-adenosine triphosphatase) inhibitors
(PPIs) have been available in acid-suppressing agents since the
mid-1980s. Having demonstrated measureable safety and
effectiveness for the treatment of acid-related disorders, PPIs
have been widely used for the treatment of gastric ulcers,
duodenal ulcers, and reflux esophagitis. Omeprazole (OMP),
the earliest PPI available, has been used for the treatment of
acid-related disorders for decades, and has existed as a func-
tional PPI longer than any other PPI in its initial form. In
addition to its antiacid characteristic, the metabolic and mo-
lecular effects of PPI utilization, particularly when taken long-
term have grown as issues of substantial discussion. Recently,
PPIs have been described as potential antiproliferative agents
and a resistance modulator both in in vitro and in vivo xeno-
graft tumors of mice.14,15 However, the inhibitory or promo-
tional effect of PPIs for gastric inflammation and
carcinogenesis remains controversial.16,17
In animal models, H. pylori infection induces gastric cancer
in Mongolian gerbils and transgenic expression of H. pylori
protein CagA could induce gastrointestinal and hematopoietic
neoplasms.18,19 The molecular mechanisms responsible for the
anti-inflammatory effects of PPIs include its interference in NF-
kB activation, which attenuates chemokines expressions result-
ing in gastric mucosal inflammation,20,21 and inhibits adhesion
molecule expression located on polymorphonuclear neutrophil
as well as vascular endothelial cells.22 The suggestion that PPIs
could downregulate H. pylori-induced angiogenesis indicates
that PPIs have therapeutic potential for carcinogenesis.17 How-
ever, a recent animal study suggests that long-term PPI admin-
istration promotes development of adenocarcinoma, which is
associated with the progression of atrophic corpus gastritis in
Mongolian gerbils infected with H pylori.16
The interaction of H. pylori, host, and PPIs may be a
multifactor and complex process. The molecular mechanisms
involved in the inhibitory effects of OMP on the expression of
inflammatory-related mediators are not fully understood.
Moreover, there is little molecular evidence relating to the
effects of OMP on NF-kB activation and the expression of IL-
6, IL-8, and COX-2 in H. pylori-infected gastric mucosa.
In the present study, we aimed to investigate the effects of
OMP in CagA positive (CagAþ) and negative (CagAe) H.pylori-treated gastric cells, specifically, the effects of OMP on
NF-kB activation and phosphorylation of IkB. The extent
expression of inflammatory mediators COX-2, IL-6, and IL-8
were also measured.
2. Methods2.1. MaterialsThe pure compound OMP (SigmaeAldrich Japan, Tokyo,
Japan) was dissolved into dimethylsulfoxide as stock solution,
and diluted to appropriate experimental concentrations with
RPMI1640 medium before use. All other chemicals were
obtained from SigmaeAldrich.2.2. Cell cultureThe gastric cancer cell line Kato III was purchased from the
Bioresource Collection and Research Center, Food Industry
Research and Development Institute (Hsinchu, Taiwan). Kato
III cells were cultured in RPMI 1640 medium containing 10%
heat-inactivated fetal bovine serum, 100 units/mL of peni-
cillin, and 100 mg/mL of streptomycin in a humidified incu-
bator at 37C and 5% CO2.2.3. Bacterial strains and preparation of H. pylori water
extractH. pylori strain ATCC 43504 (CagAþ) and H. pylori strain
ATCC 51932 (CagAe) were selected for this study. These
strains were cultured for 3 days on horse blood agar plates in a
microaerophilic milieu (15% CO2) at 37
C. The H. pylori
extracts (HPE) were prepared as previously described with
some modifications.23 Briefly, bacteria in the exponential
growth phase were harvested with sterile cotton swabs from
the blood agar plates, and suspended in distilled water, using a
concentration of 1.0 mL per plate (from 109 to 1010 bacteria).
The cell suspension was kept at room temperature for 20
minutes before centrifugation at 20,000g for 15 minutes. The
resultant supernatant was considered as the initial water
extract. No preservatives were added, and the extract was
stored at 70C until further use. Before use, the water extract
was thawed at room temperature and centrifuged at 30,000g
for 20 minutes. To remove most of the high molecular weight
material (i.e., primarily membrane vesicles and whole
flagella), the supernatant was passaged through a 0.2 mm
syringe-adapted filter (Millipore Corp., Bedford, MA, USA).
The Bradford assay (Bio-Rad, Hercules, CA, USA) was used
for quantitative protein determinations, with bovine serum
albumin serving as the standard. The resulting extracts
(200 mg/mL) were diluted to 0.1% (v/v) in growth medium
before use.232.4. Western blot analysisKato-III cells were incubated for 18 hours in culture me-
dium lacking supplements prior to treatment. Preparations
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ence of OMP (105M) for 24 hours. Cells were then washed
twice with ice-cold PBS, dislodged with a scraper, and lysed
in 250 mL of sample buffer (i.e. 62.5 mM of TriseHCl, 2% of
SDS, 10% of glycerol, 50 mM of dithiothreitol, and 0.1% of
bromophenol blue; pH 6.8). Proteins (15e20 mg) were
separated via 10% SDS-polyacrylamide gel electrophoresis
and transferred electrophoretically onto nitrocellulose mem-
branes. Membranes were then blocked with buffer (i.e..
20 mM of TriseHCl, 140 mM of NaCl, 0.1% of Tween 20,
and 5% of skim milk powder; pH 7.6) and probed with pri-
mary anti-NF-kB, anti-IkB, anti-phosphorylated IkB (Cell
Signaling Technology; Beverly, MA, USA), and anti-b actin
(SigmaeAldrich) antibodies. The bound antibodies were
detected with horseradish peroxidase-conjugated anti-mouse
antibodies via an enhanced chemiluminescence ECL system
(Amersham, Buckinghamshire, UK) and exposure of mem-
branes to Kodak X-Omat films.2.5. Quantitative real-time polymerase chain reactionKato-III cells were incubated for 18 hours in culture me-
dium lacking supplements prior to treatments. Preparations
were treated with HPE (200 ng/mL) in the absence or presence
of OMP (105M) for 24 hours. Total RNA of extracts was
obtained using the total RNA Isolation kit according to the
manufacturer's instructions (Qiagen GmbH, Hilden, Ger-
many). The yield and purity of extracted RNA were deter-
mined using the 260:280 nm absorbance ratio. The reverse
transcription reaction was performed with 2 mg of total RNA,
which was previously reverse transcribed into cDNA with
oligo (dT) primers. The quantitative real time polymerase
chain reaction (qPCR) analysis was carried out with an iScript
cDNA synthesis kit (Bio-Rad, Berkeley, CA, USA.). All
cDNA preparations were diluted at a 1:10 ratio with RNase
free water before qPCR. All qPCR reactions were performed
in a total volume of 25 mL, consisting of 1 mL of cDNA,
12.5 mL of iQ SYBR Green supermix (2; Bio-Rad) primer
pairs, as listed in Table 1. Each biological replicate was run in
triplicate on a CFX96 real-time PCR detection system (Bio-
Rad). The cycling conditions were 10 minutes of polymeraseTable 1
Real-time quantitative polymerase chain reaction primers.










COX ¼ cyclooxygenase; GAPDH ¼ glyceraldehyde 3-phosphate dehydro-
genase; IL ¼ interleukin.activation at 95C followed by 40 cycles at 95C for 15 sec-
onds and 65C for 60 seconds. The threshold was set above the
nontemplate control background and within the linear phase to
target gene amplification and calculate the cycle at which the
transcript was detected. Melting curves were also generated to
confirm the single gene-specific peak, and nontemplate con-
trols were included in each run to control for contaminations.2.6. Statistical analysisAll experiments were carried out at least three times; data
points in each assay represent measurement means from
triplicate samples. Data are expressed as mean ± standard
deviation. Differences between two groups were determined
via the independent t test. In all cases, a p < 0.05 was
considered to be statistically significant.
3. Results3.1. Effects of OMP on NF-kB activation in Kato-III
cellsAs shown in Fig. 1, both CagAþ and CagA HPE (10%)
induced NF-kB activation. CagA HPE-induced NF-kB acti-
vation was suppressed with a cotreatment of OMP. An incu-
bation of these cells in HPE with or without OMP did not
affect the expression of IkB. However, the phosphorylation of
IkB was clearly suppressed by an OMP treatment of these
cells with or without CagAe HPE.3.2. Effects of HPE and OMP on COX-2 expression in
Kato-III cellsThe treatment of Kato-III cells with CagAþ or CagA HPE
increased the expression of COX-2 mRNA (Fig. 2). Further-
more, treatment with OMP alone did not affect the expression
of COX-2. OMP reduced COX-2 transcription following
CagA HPE treatment. Conversely, OMP augmented COX-2
transcription induced via CagAþ HPE.3.3. Effects of HPE and OMP on IL-6 expression in
Kato-III cellsThe treatment of Kato-III cells with CagAþ or CagA HPE
did not affect IL-6 mRNA expression (Fig. 3). OMP treatment
alone reduced IL-6 expression. Additionally, CagA HPE
cotreatment with OMP also suppressed IL-6 expression.3.4. Effects of HPE and OMP on IL-8 expression in
Kato-III cellsThe treatment of Kato-III cells with OMP, CagAþ or
CagA HPE alone did not affect IL-8 mRNA expression
significantly (Fig. 4). However, cotreatment of OMP with
CagA HPE, OMP suppressed CagA HPE-induced IL-8
transcription.
Fig. 1. Helicobacter pylori extract (HPE) regulated nuclear factor (NF)-kB and
IkB expression, whereas omeprazole (OMP) inhibited NF-kB up-regulation in
Kato-III cells. The expression of NF-kB, IkB, phospho-IkB, and b-actin in
unstimulated Kato-III cells (Lane 1), Kato-III cells treated with OMP (10-5 M;
Lane 2), and Kato-III cells stimulated with HPE containing either ATCC43504
or ATCC51932 in the absence (Lanes 3 and 4, respectively) and presence of
OMP (Lanes 5 and 6, respectively) are presented above. Cell lysates were
analyzed via immunoblotting using anti-NF-kB, anti-IkB, and anti-phospho-
IkB antibodies. Cell lysates were also probed with the anti-b-actin antibody to
confirm equal loading of protein.
Fig. 3. The effects of Helicobacter pylori extract and omeprazole (OMP) on
interleukin (IL)-6 expression in Kato-III cells. IL-6 expression was measured
with quantitative polymerase chain reaction. Data are expressed as
mean ± standard deviation. *p < 0.05 vs. control; **p < 0.001 vs. no OMP
treatment group.
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In this study, HPE and OMP affected NF-kB expression and
phosphorylation of IkB in Kato-III cells. CagAþ HPE and
CagA HPE could induce NF-kB and COX-2 gene expression,
but not IL-6 and IL-8 expression. OMP suppressed NF-kB
expression in CagA HPE treated cells, but not in CagAþ HPEFig. 2. The effects of Helicobacter pylori extract and omeprazole (OMP) on
cyclooxygenase (COX)-2 expression in Kato-III cells. COX-2 expression was
measured with quantitative polymerase chain reaction. Data are expressed as
mean ± standard deviation. *p < 0.05 vs. control; **p < 0.001 vs. control;
***p < 0.05 vs. no OMP treatment group; and ****p < 0.001 vs. no OMP
treatment group.treated cells. OMP only magnified COX-2 expression (not IL-
6 and IL-8) in CagAþ HPE cells, but suppressed COX-2, IL-6,
and IL-8 expression in CagA HPE cells.
Based on the presence or absence of CagA, H. pylori can be
divided into either CagAþ or CagA strains.24,25 An infection
resulting from the CagAþ H. pylori has been associated with
higher grades of gastric mucosal inflammation and severe
atrophic gastritis, and is thought to play an important role inFig. 4. The effects of Helicobacter pylori extract and omeperazole (OMP) on
interleukin (IL)-8 expression in Kato-III cells. IL-8 expression was measured
with quantitative polymerase chain reaction. Data are expressed as
mean ± standard deviation. *p < 0.05 vs. no OMP treatment group.
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bacterium-derived oncoprotein that acts in mammals, which
further indicates the importance of CagA tyrosine phosphor-
ylation. This enables CagA to deregulate the proteinetyrosine
phosphatase SHP-2 in the development of H. pylori-associated
neoplasms. Transgenic expression of H. pylori CagA induces
gastrointestinal and hematopoietic neoplasms in mouse.19
Furthermore, NF-kB could trigger H. pylori-initiated
gastritis by inducing proinflammatory cytokines. Most stimuli
activate NF-kB via the IkB kinase-mediated phosphorylation
of inhibitory molecules (e.g., IkB at N-terminal serine resi-
dues). Although the evidence concerning the mechanisms that
may regulate NF-kB in an H. pylori infection is equivocal, it
appears that IkB kinase activity is required.29 H. pylori in-
duces NF-kB in a CagA-independent manner.10 Our findings
corroborate this observation, as we found that the stimulation
of cells with both CagAþ and CagAe HPE resulted in the
nuclear translocation of NF-kB. We also demonstrated that
CagAþ H. pylori may possess a more remarkable effect on
NF-kB activation than the CagA strain due to its unapparent
IkB phosphorylation. Furthermore, the amplified activation of
NF-kB was clearly prevented with OMP treatment in CagA
HPE treated condition. Additionally, with CagAþ HPE treat-
ment, OMP promoted COX-2 expression, but not for IL-6 and
IL-8 expression. On the contrary, OMP suppressed COX-2, IL-
6, and IL-8 expression in CagA HPE-treated cells. These
results suggest that OMP dysregulates NF-kB activation and
suppresses COX-2, IL-6, and IL-8 production in Kato-III cells
model. Possibly, OMP may have different molecular effects in
CagAþ and CagA H. pylori infections.
OMP is widely used clinically due to its potent inhibitory
effects on acid secretion. Furthermore, OMP appears to have a
wide therapeutic range, in that it not only inhibits acid
secretion,30,31 but also may possess anti-inflammatory20 and
anticancer properties22; however, its underlying molecular
mechanisms remain unclear. The mechanisms by which OMP
suppresses gastric acid secretion have been shown to be
dependent on its inhibition of the Hþ/Kþ ATPase present on
the membrane of gastric parietal cells, and subsequent inhi-
bition of Hþ release. In addition, OMP can affect the trans-
migration of leukocytes from vessels to inflammatory sites via
several mechanisms. OMP can inhibit the expression of
adhesion molecules on neutrophils and vascular endothelial
cells, as well as the proinflammatory response by suppressing
IL-8 production in gastric and endothelial cells via the pre-
vention of NF-kB nuclear translocation and activation.20
To determine whether other PPIs such as lanoprazole,
pantoprazole, and esomeprazole also have similar responses as
those of OMP found in our study requires further study. The
extent to which normal gastric mucosa also has a similar
response to the Kato-III cell line, a human gastric cancer cell
line, also necessitates additional clarification.
The interactions of H. pylori CagA proteins, host cells, and
PPIs are complex processes, which possibly related to gastric
inflammation and carcinogenesis. OMP attended the complex
signaling processes of H. pylori infections and is involved in
antiproliferative and anti-inflammatory mechanisms.Acknowledgments
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